1. Home
  2. CRSP vs RELY Comparison

CRSP vs RELY Comparison

Compare CRSP & RELY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$52.09

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo Remitly Global Inc.

RELY

Remitly Global Inc.

HOLD

Current Price

$22.11

Market Cap

5.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
RELY
Founded
2013
2011
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.0B
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
CRSP
RELY
Price
$52.09
$22.11
Analyst Decision
Buy
Buy
Analyst Count
17
7
Target Price
$70.29
$22.86
AVG Volume (30 Days)
1.3M
3.0M
Earning Date
05-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
263.16
EPS
N/A
1.16
Revenue
$289,590,000.00
$1,635,147,000.00
Revenue This Year
$807.72
$21.89
Revenue Next Year
$172.52
$19.17
P/E Ratio
N/A
$20.78
Revenue Growth
9169.85
29.37
52 Week Low
$44.12
$12.08
52 Week High
$78.48
$27.48

Technical Indicators

Market Signals
Indicator
CRSP
RELY
Relative Strength Index (RSI) 40.53 35.68
Support Level $50.45 $12.55
Resistance Level $60.41 $25.16
Average True Range (ATR) 2.27 1.21
MACD -0.79 -0.45
Stochastic Oscillator 4.25 6.69

Price Performance

Historical Comparison
CRSP
RELY

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About RELY Remitly Global Inc.

Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. The company's revenue is generated from transaction fees charged to customers, and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.

Share on Social Networks: